The price target on Vertex Pharmaceuticals was raised to $525 from $456 at Leerink


Leerink raised the company’s target price about Vertex Pharmaceuticals (VRTX) to $525 from $456 and maintains an outperform rating on the stock. The company cites an increase in its terminal growth assumption from 1% to 2%. Leerink is bullish on the company’s revenue and outlook, which he expects to drive share price performance. The company would caution that it projects higher growth in investment spending than consensus models.

First published in The Fly – the ultimate source for breaking, real-time market-moving financial news. Try now >>

Check out the best stocks recommended by analysts >>

Read more about VRTX:

Disclaimer and DisclosureReport a problem



Source link

  • Related Posts

    8K Edgemode Form For: 31 December

    8K Edgemode Form For: 31 December Source link

    Analyst Report: Campbell Soup Co.

    Analyst Report: Campbell Soup Co. Source link

    Leave a Reply

    Your email address will not be published. Required fields are marked *